Introduction {#s1}
============

Tuberculosis (TB) has had a devastating impact on public health in Africa \[[@C1], [@C2]\]. In 2018, out of the 10.0 million cases notified, 24% were from the sub-Saharan countries \[[@C3]\]. Of concern is that the region accounts for 80% of the 1.8 million estimated annual deaths related to TB; this is a disproportionate impact in terms of mortality \[[@C4]\]. Namibia, with a case notification rate of 442 cases per 100 000, is ranked fifth among countries with highest burden of TB \[[@C5], [@C6]\]. However, the universal access to community-based TB care through the Stop-TB and End-TB strategies implemented since 2005 has improved case identification and treatment outcomes in Namibia \[[@C7]\].

Nevertheless, the gradual rise in incidence of drug-resistant TB (DR-TB) and poor treatment outcomes such as "lost-to-follow-up" (LTFU) (*i.e.* an interruption of TB treatment for at least two consecutive months) and death \[[@C7]--[@C10]\] are major barriers to ending TB in Namibia \[[@C3], [@C11]--[@C14]\]. For instance, the incidence of LTFU among notified cases in Namibia increased from 4% in 2014 to 10% in 2015. Studies in other low and middle-income countries (LMICs) such as India and Malaysia estimate higher incidences of LTFU at 19.2 and 24%, respectively \[[@C15], [@C16]\]. In addition, LTFU is an important risk factor for re-emergence of TB strains resistant to first-line anti-TB drugs \[[@C6]\]. In 2014, an estimated 300 000 cases of multidrug-resistant (MDR) TB (*i.e.* resistance to backbone first-line anti-TB medicines, rifampicin and isoniazid) were notified globally \[[@C17]\]. In the same year Namibia notified 137 MDR-TB and 6 extensively drug-resistant (XDR) TB (*i.e.* MDR-TB with resistance to second-line TB drugs, aminoglycosides and/or fluoroquinolones) cases \[[@C10]\].

The significance of risk factors of LTFU (*i.e.* patient demographics, socioeconomic status, directly observed treatment, short-course (DOTS) programme, clinical covariates, TB treatment regimen and HIV co-infection) on LTFU have been contested across countries \[[@C10], [@C14], [@C15], [@C18]--[@C24]\]. In Namibia, despite universal coverage of high-quality DOTS, little is known about the impact of these factors on poor treatment outcomes and, in particular, LTFU, hence, the current study intended to determine the prevalence and determinants of LTFU in the Namibian context.

Methods {#s2}
=======

Study design and population {#s2a}
---------------------------

The target population was all the new and retreatment cases with drug-sensitive TB initiated on first-line anti-tuberculosis DOTS regimens. The accessible population was TB cases registered in the National Electronic Tuberculosis Register (ETR) database over a 10-year period from 2006 to 2015. The study included all 104 300 TB cases registered in the ETR; 3775 of these were LTFU. A patient was considered LTFU if TB treatment was interrupted for 2 months or more \[[@C10], [@C17]\]. A retrospective cohort analysis for trends and predictors of LTFU was conducted. Quarterly trends in LTFU of TB cases in Namibia were analysed as a proportion of the total number of TB cases registered for each quarter. The main outcome measure was the effect size (*i.e.* odds ratio) for predictors for LTFU compared to TB cases that had a successful treatment outcome (*i.e.* cured or completed treatment). The study excluded all TB cases whose treatment outcome had not been registered in the ETR at the time of the study and patients with poor treatment outcome other than LTFU, (*i.e.* died, transferred out, treatment failure) ([figure 1](#F1){ref-type="fig"}). FIGURE 1Flowchart for tuberculosis (TB) cases included in the analysis. ETR: electronic tuberculosis register; LTFU: lost to follow-up.

Medium-term plans for TB in Namibia {#s2b}
-----------------------------------

Since 2004, Namibia has implemented the DOTS strategy under a national strategic plan on TB implemented under 5-year medium-term plans (MTPs) to improve outcomes. The first MTP was implemented between 2004--2009, with the main goal of scaling up DOTS to all public health facilities in Namibia, with the main goal of achieving 85% treatment success rate from 65%, and to strengthen detection and management of TB cases. The second MTP-II was developed to address gaps in MTP-I and was implemented between 2015 and 2017 to meet the World Health Organization (WHO) and national targets for TB. This focused mainly on the expansion and enhancement of access to quality TB treatment, bacteriological testing and community-based interventions for reduction of cases LTFU. Thus, the difference in the interventions served as discriminates to assess the effectiveness the two mid-term policy strategies for time-series analysis \[[@C8], [@C9]\]

Procedure and data analysis {#s2c}
---------------------------

Data on treatment outcome, patient sociodemographic, clinical and treatment characteristics were extracted from the ETR and exported to R-Studio software (version 3.3.2) for quantitative analysis. The main outcome measures were an odds ratio of a TB case registered under DOTS programme getting LTFU relative to those with a successful treatment outcome (*i.e.* cured or completed). The covariates included in the model were patient characteristics, clinical/diagnostic, treatment and DOTS programmatic characteristics. The patient covariates were age, sex and region of residence. The clinical covariates were diagnostic or laboratory classification of the TB case, sputum conversion at 2 months and HIV co-infection. The programmatic covariates were the TB strategies implemented (*i.e.* the first and second MTP for TB and leprosy), DOTS support category and level of health facility. Other clinical covariates pertained to the treatment regimens and therapy included the DOTS regimen initiated, anti-retroviral treatment (ART) regimen, type of DOTS provider, and previous prophylaxis with co-trimoxazole preventive therapy (CPT) and isoniazid preventive therapy (IPT). An interrupted time-series analysis was performed to determine the changes in level and trend of LTFU among TB cases registered in the DOTS programme during the implementation of MTP-I (2004--2009) and MTP-II (2010--2015) medium-term strategies for TB in Namibia. The following segmented regression model was used:

Where, *Y~t~* is the outcome (*i.e.* proportion of patients LTFU at time *t*), *T* is the time (in years) elapsed since the start of the study, *X~t~* is a dummy variable indicating the pre-intervention period (coded 0) or the post-intervention period (coded 1); *β*~0~ estimates the baseline outcome at *T*=0; *β*~1~ is an estimate of the pre-intervention outcome trend (*i.e.* the change in outcome with time); *β*~2~ is an estimate of the change in outcome immediately after the intervention (*i.e.* compared to the outcome at the end of the pre-intervention period); *β*~3~ estimates the change in the post-intervention outcome trend compared to the pre-intervention outcome trend; *e~t~* represents the random variability not explained by the model. Adjustment for serial autocorrelation was carried out by using the Durbin--Watson statistic and by including an autocorrelation parameter in the segmented regression model if necessary.

Bivariate analysis using Chi-squared test or crude odds ratios was used to identify factors associated with LTFU. Significant factors were subsequently included in the multivariate logistic regression analysis to adjust odds ratios for confounding for independent predictors for LTFU and to elaborate on the relationships between multiple variables. The level of significance for the bivariate and multivariate analyses for a 95% confidence interval was set at a type I error α of 0.05 and β of 0.20 (power 80%) to detect a significant odds ratio \[[@C18]\].

Ethics {#s2d}
------

The research and ethics committees of the Ministry of Health and Social Services (MoHSS) (17/3/3/November 2015) and University of Namibia (SOM/114/2016) approved the study. The need for written informed patient consent was waived as the study used retrospective records in the ETR database. Patient-specific identifiers, such as names, were anonymized or were not extracted or included from the dataset to ensure confidentiality.

Results {#s3}
=======

A significant decline in the quarterly trends in LTFU between 2006 and 2015 of 2.5 cases per quarter (R^2^=0.45) was observed ([figure 2](#F2){ref-type="fig"} and [table 2](#TB2){ref-type="table"}). There was a statistically significant decline in the cases of LTFU per quarter −0.23% (p\<0.001) during MTP-I. The cases of LTFU increased slightly at start of MTP-II. The quarterly trend in LTFU significantly increased by 0.16% (p=0.044) during MTP-II relative to MTP-I ([figure 2](#F2){ref-type="fig"} and [table 1](#TB1){ref-type="table"}).

![Trends of lost to follow-up cases in Namibia, 2006--2015. TB: tuberculosis; Q: quarter.](00030-2019.02){#F2}

###### 

Model for impact of medium-term plans (MTPs) on loss to follow-up (LTFU)

  **Coefficients**                                **Estimate (95% CI)**   **[se]{.smallcaps}**   **t-value**   **p-value**
  ---------------------------------------------- ----------------------- ---------------------- ------------- -------------
  **Level of LTFU at start of MTP-I (*β*~0~)**      6.67 (5.33--8.04)             0.67              9.93       0.0001^\*^
  **Trend in LTFU in MTP-I (*β*~1~)**             −0.23 (−0.37-- −0.09)           0.07              −3.32        0.002\*
  **Level change in LTFU in MTP-II (*β*~2~)**      0.71 (−0.93--2.35)             0.81              0.88          0.385
  **Trend change in LTFU in MTP-II (*β*~3~)**      0.16 (0.004--0.32)             0.08              2.08         0.044\*

\*: *p*\<0.05.

###### 

Characteristics and factors associated with tuberculosis (TB) cases lost to follow-up (LTFU) in Namibia

  **Characteristic**                              **Total**      **TB treatment outcome**     **df**      **cOR (95% CI)**     **p-value**     
  ------------------------------------------- ----------------- -------------------------- ------------- ------------------ ------------------ ---------
  **All TB cases**                             65 113 (100.0%)        61 338 (94.2%)        3775 (5.8%)                                        
  **TB strategy employed**                                                                                                                     
   MTP-I                                       30 771 (100.0%)        28 766 (93.5%)        2005 (6.5%)          1            1.3 (1.2--1.4)    0.000\*
   MTP-II                                      34 342 (100.0%)        32 572 (94.8%)        1770 (5.2%)                             1          
  **Region**                                                                                                                                   
   Khomas                                      13 137 (100.0%)        12 105 (92.1%)        1032 (7.9%)          13           1.1 (0.9--1.4)    0.000\*
   Kavango West                                 4572 (100.0%)          4335 (94.8%)         237 (5.2%)                        0.7 (0.5--0.9)     0.410
   Zambezi                                      2788 (100.0%)          2726 (97.8%)          62 (2.2%)                        0.3 (0.2--0.4)    0.007\*
   Otjozondjupa                                 4021 (100.0%)          3698 (92.0%)         323 (8.0%)                        1.1 (0.9--1.4)    0.000\*
   Erongo                                       7852 (100.0%)          7588 (96.6%)         264 (3.4%)                        0.4 (0.3--0.6)     0.340
   Karas                                        4122 (100.0%)          3859 (93.6%)         263 (6.4%)                        0.9 (0.7--1.1)    0.000\*
   Hardap                                       2660 (100.0%)          2522 (94.8%)         138 (5.2%)                        0.7 (0.5--0.9)     0.313
   Kunene                                       2069 (100.0%)          1897 (91.7%)         172 (8.3%)                        1.2 (0.9--1.5)    0.013\*
   Ohangwena                                    6248 (100.0%)          5903 (94.5%)         345 (5.5%)                        0.8 (0.6--1.0)     0.251
   Omaheke                                      2847 (100.0%)          2822 (99.1%)          25 (0.9%)                        0.1 (0.1--0.2)    0.022\*
   Oshikoto                                     6331 (100.0%)          5885 (93.0%)         446 (7.0%)                        0.9 (0.8--1.2)    0.000\*
   Oshana                                       1593 (100.0%)          1508 (94.7%)          85 (5.3%)                        0.7 (0.5--1.0)     0.851
   Omusati                                      5650 (100.0%)          5355 (94.8%)         295 (5.2%)                        0.7 (0.5--0.9)    0.042\*
   Kavango East                                 1223 (100.0%)          1135 (92.8%)          88 (7.2%)                              1           0.007\*
  **Health facility**                                                                                                                          
   Hospital                                    13 334 (100.0%)        12 348 (92.6%)        986 (7.4%)           2            1.4 (1.2--1.5)    0.000\*
   PHC clinic                                  41 454 (100.0%)        39 240 (94.7%)        2214 (5.3%)                      1.0 (0.9-- 1--1)   0.000\*
   Health centre                               10 325 (100.0%)         9750 (94.4%)         575 (5.6%)                              1            0.358
  **Sex**                                                                                                                                      
   Male                                        37 479 (100.0%)        34 986 (93.3%)        2493 (6.7%)          1            1.5 (1.4--1.6)    0.000\*
   Female                                      27 634 (100.0%)        26 352 (95.4%)        1282 (4.6%)                             1          
  **Age years mean±[sd]{.smallcaps}**               1.27                33.5±16.9            33.9±16.4                                          0.000\*
  **Age categories years**                                                                                                                     
   0--4                                         4420 (100.0%)          4191 (94.8%)         229 (5.2%)           7            0.9 (0.7--1.1)    0.000\*
   5--14                                        3901 (100.0%)          3729 (95.6%)         172 (4.4%)                        0.7 (0.6--0.9)     0.202
   15--24                                       8251 (100.0%)          7766 (94.1%)         485 (5.9%)                        1.0 (0.8--1.2)    0.006\*
   25--34                                      18 760 (100.0%)        17 564 (93.6%)        1196 (6.4%)                       1.1 (0.9--1.3)     0.976
   35--44                                      15 447 (100.0%)        14 567 (94.3%)        880 (5.7%)                        0.9 (0.8--1.1)     0.280
   45--54                                         7734 (0%)            7292 (94.3%)         442 (5.7%)                        0.9 (0.8--1.2)     0.718
   55--64                                       3547 (100.0%)          3355 (94.6%)         192 (5.4%)                        0.9 (0.7--1.1)     0.766
   ≥65                                          3053 (100.0%)          2874 (94.1%)         179 (5.9%)                              1            0.429
  **First-line TB regimen**                                                                                                                    
   2 HRZE/4 HRE                                49 226 (100.0%)        46 673 (94.8%)        2553 (5.2%)                       0.7 (0.4--1.1)    0.000\*
   2 HRZES/1 HRZE/5 HRE                        10 846 (100.0%)         9883 (91.1%)         963 (8.9%)           4            1.2 (0.8--2.0)     0.135
   2 HRZS/1 HRZ/5 HR (children)                 304 (100.0%)           288 (94.7%)           16 (5.3%)                        0.7 (0.4--1.4)     0.360
   2 HRZ/4 HR (children)                        4475 (100.0%)          4251 (95.0%)         224 (5.0%)                        0.6 (0.4--1.1)     0.329
   Other regimens                               262 (100.0%)           243 (92.7%)           19 (7.3%)                              1            0.111
  **TB case registered**                                                                                                                       
   New                                         53 956 (100.0%)        51 162 (94.8%)        2794 (5.2%)          5            0.7 (0.6--0.8)    0.000\*
   Failure                                      402 (100.0%)           370 (92.0%)           32 (8.0%)                        1.2 (0.8--1.7)    0.000\*
   Other previously treated                     2769 (100.0%)          2508 (90.6%)         261 (9.4%)                        1.4 (1.2--1.6)     0.465
   Readmission                                  842 (100.0%)           674 (80.0%)          168 (20.0%)                       3.3 (2.7--4.0)    0.000\*
   Recurrent TB                                 1069 (100.0%)          974 (91.1%)           95 (8.9%)                        1.3 (1.1--1.6)    0.000\*
   Relapse                                      6075 (100.0%)          5650 (93.0%)         425 (7.0%)                              1            0.029
  **TB case**                                                                                                                                  
   New TB case                                 53 956 (100.0%)        51 162 (94.8%)        2794 (5.2%)          1            0.6 (0.5--0.6)    0.000\*
   Previously treated                          11 157 (100.0%)        10 176 (91.2%)        981 (8.8%)                              1          
  **Pulmonary TB case**                        52 454 (100.0%)        49 345 (94.1%)        3109 (5.9%)          1            1.1 (1.0--1.2)    0.004\*
  **Extrapulmonary TB**                        12 659 (100.0%)        11 993 (94.7%)        666 (5.3%)                              1          
  **Site of TB infection**                                                                                                                     
   Pulmonary                                   52 273 (100.0%)        49 165 (94.1%)        3108 (5.9%)          6            0.9 (0.6--1.2)    0.000\*
   Lymph nodes                                  1806 (100.0%)          1732 (95.9%)          74 (4.1%)                        0.6 (0.4--0.9)     0.347
   Meningitis                                   731 (100.0%)           680 (93.0%)           51 (7.0%)                        1.0 (0.7--1.6)    0.006\*
   Miliary                                      781 (100.0%)           740 (94.8%)           41 (5.2%)                        0.8 (0.5--1.2)     0.928
   Other sites                                  3509 (100.0%)          3295 (93.9%)         214 (6.1%)                        0.9 (0.6--1.2)     0.211
   Pleura                                       5400 (100.0%)          515 5(95.5%)         245 (4.5%)                        0.6 (0.4--0.9)     0.476
   Bones/joints                                 613 (100.0%)           571 (93.1%)           42 (6.9%)                              1           0.011\*
  **DOTS provider**                                                                                                                            
   Guardian (relative/neighbour)               24 974 (100.0%)        23 482 (94.0%)        1492 (6.0%)          4            0.4 (0.3--0.6)    0.000\*
   Workplace                                    592 (100.0%)           566 (95.6%)           26 (4.4%)                        0.3 (0.2--0.5)    0.000\*
   Health facility                             22 577 (100.0%)        21 462 (95.1%)        1115 (4.9%)                       0.4 (0.2--0.5)    0.000\*
   Community health worker                      1262 (100.0%)          1230 (97.5%)          32 (2.5%)                        0.2 (0.1--0.3)    0.000\*
   Other                                        295 (100.0%)           257 (87.1%)          38 (12.9%)                              1           0.000\*
  **Baseline sputum smear**                                                                                                                    
   Smear negative                              12 265 (100.0%)        11 544 (94.1%)        721 (5.9%)           2            1.0 (0.9--1.0)    0.005\*
   Smear positive                              30 863 (100.0%)        29 165 (94.5%)        1698 (5.5%)                       0.9 (0.8--1.0)     0.282
   Smear not done                              21 985 (100.0%)        20 629 (93.8%)        1356 (6.2%)                             1            0.001
  **Sputum not converted**                                                                                                                     
   Yes                                         36 769 (100.0%)        33 521 (91.2%)        3248 (8.8%)          1            5.1 (4.7--5.6)    0.000\*
   No                                          28 343 (100.0%)        27 816 (98.1%)        527 (1.9%)                              1          
  **Sputum smear month 2**                                                                                                                     
   Converted to smear negative                 16 992 (100.0%)        16 73 5(98.5%)        257 (1.5%)           2           0.1 (0.10--0.13)   0.000\*
   Remaining smear positive                     2043 (100.0%)          1971 (96.5%)          72 (3.5%)                        0.3 (0.2--0.4)    0.000\*
   Defaulted+died+transferred+not available    11 829 (100.0%)        10 460 (88.4%)        1369 (11.6%                             1           0.000\*
  **On ART therapy**                                                                                                                           
   No                                           8276 (100.0%)          7713 (93.2%)         563 (6.8%)           1            1.6 (1.4--1.8)    0.000\*
   Yes                                         13 793 (100.0%)        13 184 (95.6%)        609 (4.4%)                              1          
  **Exposure to IPT**                                                                                                                          
   Yes                                          8713 (100.0%)          8256 (94.8%)         457 (5.2%)           1            1.8 (0.9--3.7)     0.096
   No                                           272 (100.0%)           264 (97.1%)           8 (2.9%)                               1          
  **HIV CPT initiated**                                                                                                                        
   No                                           4347 (100.0%)          4103 (94.4%)         244 (5.6%0           1            0.9 (0.8--1.1)     0.912
   Yes                                         19 484 (100.0%)        18 382 (94.3%)        1102 (5.7%)                             1          
  **HIV status**                                                                                                                               
   Negative                                    22 719 (100.0%)        21 752 (95.7%)        967 (4.3%)           2           0.6 (0.5-- 0.6)    0.000\*
   Positive                                    22 506 (100.0%)        21 243 (94.4%)        1263 (5.6%)                       0.7 (0.6--0.8)    0.000\*
   Unknown                                      4012 (100.0%)          3713 (92.5%)         299 (7.5%)                              1           0.000\*

df: degrees of freedom; cOR: crude odds ratio; MTP: medium-term plan; PHC: primary healthcare; HRZE: isoniazid/rifampicin/pyrazinamide/ethambutol; HRE: isoniazid/rifampicin/ethambutol; DOTS: directly observed treatment short-course; ART: anti-retroviral treatment; IPT: isoniazid preventive therapy; CPT: co-trimoxazole preventive therapy. \*: p\<0.05.

Out of the 104 603 TB cases registered, 3775 (3.6%) were LTFU; this ranged between 6.7% and 34.4% by regions in Namibia. The prevalence of cases LTFU among patients with unsuccessful treatment outcomes was 24.3% (3775 of 15 518; [table 2](#TB2){ref-type="table"}). The majority of patients LTFU were: male (66%), new TB cases (74.4%), aged between 25 and 34 years (31.7%), registered at primary healthcare (PHC) clinics (58.6%), with a diagnosis of pulmonary TB (82.4%), initiated on the standard 2HRZE/4HRE, *i.e* 2 months of isoniazid/rifampicin/pyrazinamide/ethambutol combination continued with 4 months of isoniazid/rifampicin/pyrazinamide/ethambutol regimen (73.6%), and registered during the implementation of the first MTP for TB (53.1%) ([figure 3](#F3){ref-type="fig"}). One-third of cases of LTFU had TB/HIV co-infection (33.5%) and the majority of sputum smears of LTFU cases were either negative or not evaluated (55.0%) at the start of treatment. A higher number of patients who were LTFU had a guardian (*i.e.* family member/relative, neighbour) as the main DOTS provider (39.4%; [table 2](#TB2){ref-type="table"}), were in the continuation phase of treatment (63.73%) and were not taking ART (83.9%). The cases of LTFU were significantly higher in regions with border, transit, and central business districts such as Khomas and Kunene (p=0.001, [figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

![Prevalence of loss to follow-up (LTFU) among tuberuculosis cases by geographic region in Namibia.](00030-2019.03){#F3}

![Absolute tuberculosis cases lost to follow-up by region in Namibia.](00030-2019.04){#F4}

The univariate logistic regression analysis showed a significant association between percentage of cases of LTFU and young/middle-aged adult patients (15--45 years) (p=0.001), male sex (p=0.001) and region where TB care was received (p=0.001), known HIV status (p=0.001) and 2-month sputum conversion (p=0.001). The medicine-related characteristics associated with LTFU: ART (p=0.001), a relative being a DOTS provider (p=0.001), type of TB regimen type (p=0.044), MoHSS MTP-I strategic plan (p=0.001), and level of healthcare facility for TB care (p=0.002) ([table 2](#TB2){ref-type="table"}).

Independent predictors of LTFU of the DOTS programme in Namibia {#s3a}
---------------------------------------------------------------

A multivariate logistic regression analysis was conducted to identify predictors of LTFU ([table 3](#TB3){ref-type="table"}). A test of the full model against was statistically significant, indicating that the predictors as a set reliably distinguished between LTFU and non-LTFU outcomes (χ^2^=36.6, p=0.001 with df=15). Nagelkerke\'s R^2^ of 0.35 indicated a relationship between prediction and grouping by LTFU. Prediction success overall was 71.7% (60.8% for LTFU and 79.7% for non-LTFU). The Wald criterion demonstrated that MTP-I strategy implemented by the National TB and Leprosy Program, male sex \[[@C19]\], type of DOTS provider \[[@C20]\], a 2-month sputum conversion; the region in Namibia of DOTS implementation; particularly Otjozondjupa, Karas and Kunene regions; and the young/middle-age categories (*i.e.* 15--45 years of age) made a significant contribution to prediction of LTFU. However, there was no further significant association of LTFU with HIV status, regimen type and level of DOTS facility.

###### 

Multivariate logistic regression for predictors of loss to follow-up in Namibia

  **Covariates**                      **aOR (95% CI)**   **p-value**
  ---------------------------------- ------------------ -------------
  **MTP for TB**                                        
   MTP period I                       0.5 (0.30--0.96)    0.037^\*^
   MTP period II                             1          
  **Region**                                            
   Karas                               18.8 (4.9--73)      0.001\*
   Otjozondjupa                       3.9 (1.0--15.6)      0.001\*
   Kunene                             3.2 (1.0-- 4.1)      0.048\*
   Khomas                              1.7 (0.13--23)      0.043\*
   Kavango West                        1.4 (0.5--4.0)       0.681
   Zambezi                             1.4 (0.5--4.0)       0.491
   Erongo                             0.4 (0.04--3.8)       0.443
   Hardap                               0 (0--10.4)         0.430
   Ohangwena                           0.6 (0.1--7.3)       1.000
   Omaheke                             1.6 (0.4--2.1)       0.641
   Oshikoto                                0 (0)            0.499
   Oshana                                0.7 (0.7)          0.999
   Kavango East                              1              0.537
  **Patient sex**                                       
   Male                                2.2 (1.3--3.8)      0.004\*
   Female                                    1          
  **Patient age years**                                 
   0--4                                  0 (0--451)        0.025\*
   5--14                              14.4 (0.5--281)       1.000
   15--24                             29.7 (3.1--194)       0.128
   25--34                             21.6 (2.4--110)      0.003\*
   35--44                             12.2 (1.4--109)      0.006\*
   45--54                             11.5 (1.2--71.6)     0.025\*
   55--64                              6.2 (0.6--0.8)      0.033\*
   ≥65                                       1              0.140
  **DOTS regimen**                                      
   2 RHZE/4 RHE                        1.0 (0.6--1.9)       0.748
   Other regimens                            1          
  **DOTS provider**                                     
   Guardian                            1.0 (0.3--4.0)      0.001\*
   Workplace                          0.8 (0.03--26.8)      0.886
   Health facility                    0.3 (0.08--1.2)       0.921
   Community health worker                 0 (0)            0.085
   Other DOTS providers                      1              0.999
  **2 month\'s sputum conversion**                      
   Smear negative                      1.6 (0.9--3.2)      0.047\*
   Smear positive                      0.4 (0.2--1.2)       0.113
   Smear not assessed                        1              0.116
  **Anti-retroviral treatment**                         
   No                                  1.9 (0.9--3.9)       0.052
   Yes                                       1          
  **HIV status**                                        
   Negative                            0.8 (0.2--3.0)       0.474
   Positive                            1.5 (0.4--6.2)       0.776
   Unknown                                   1              0.563
  **Facility level**                                    
   Hospital                            0.6 (0.2--1.9)       0.511
   PHC clinic                          0.6 (0.3--1.4)       0.437
   Health centre                             1              0.247
  **Constant**                               0              0.006

aOR: adjusted odds ratio; MTP: medium-term plan; TB: tuberculosis; DOTS: directly observed treatment, short-course; RHZE: rifampicin/isoniazid/pyrazinamide/ethambutol; RHE: rifampicin/isoniazid/ethambutol; PHC: primary healthcare. \*: p\<0.05.

Discussion {#s4}
==========

In the sample taken in this study, of all patients notified in Namibia that had a treatment outcome registered between 2006 and 2016, 1 out of every 25 TB cases registered was LTFU ([table 2](#TB2){ref-type="table"} and [figure 2](#F2){ref-type="fig"}). Furthermore, one out of four patients with unsuccessful outcomes was a case of LTFU. The prevalence of LTFU varied widely between geographical regions in Namibia, 6.6% to 34%. These are higher than the national (2%) and global benchmarks for LTFU (0%). Studies in other LMICs in Africa and Asia report the prevalence of LTFU to range between 6% and 24% \[[@C15], [@C21]\]. This calls for national and regional specific strategies to be incorporated in the medium and long-term strategic plans for TB to reduce the burden of LTFU. The strategy should target building capacity in tracing and supporting patients at risk of LTFU, particularly those registered for DOTS services in border/transit points as well as regions with central business districts.

Multivariate logistic regression suggested that the TB patients most at risk of LTFU were male patients, young adults (\<45 years), cases registered in the capital city, patients in transit and/or close to geographical border DOTS access points with high TB notification rates. Several studies have linked LTFU to patients initiated on therapy at immigration towns like borders and transit points. Similarly to our findings, studies associate higher LTFU rates among male patients \[[@C22]--[@C24]\], the youth or middle aged (34--44 years) \[[@C16], [@C23]\]. Contrary to our findings, P[eltzer]{.smallcaps} *et al*. \[[@C25]\] found no association between LTFU and male sex in a population in South Africa. Nonetheless, young adults in LMICs are a high-risk group for unemployment, HIV, alcohol and drug abuse, smoking, multiple sexual partners that predispose then to TB and poor outcomes, such as LTFU \[[@C12]--[@C15]\]. Secondly, the study demonstrated that the clinical risk factors for LTFU were new TB cases, a diagnosis of pulmonary TB *versus* extrapulmonary TB, and sputum conversion at 2 months (*i.e.* end of the intensive phase of treatment), but not HIV co-infection. Other studies found association of HIV \[[@C14]\] and regimen-related adverse drug reaction (ADR) \[[@C20]\] with LTFU among TB cases. Thirdly, the programmatic predictors of LTFU were interventions under the respective MTP strategy and DOTS support; MTP-II reduced LTFU by 50% (p=0.037). There was no association between the treatment regimen, ART and previous IPT exposure, HIV status and CPT prophylaxis and the occurrence of LTFU (p\>0.05) ([table 2](#TB2){ref-type="table"}).

Potential limitations of this study should be considered while interpreting the findings. Firstly, the retrospective data had missing information on the treatment outcome for several patients and were excluded from the analysis. In addition, we excluded cases with other poor treatment outcomes (*i.e.* death, transferred out and failure) and comparisons were made with patients who had a successful treatment outcome (*i.e.* cured and completed treatment). There may be many other factors which better explain LTFU that were not reported in the ETR database used. Nevertheless, the study utilises a nationwide dataset in a high-TB-burden country over a significant time period (10-year period). This nationwide study highlights the significance of improving socioeconomic welfare of TB patients to abate LTFU, as TB is a disease highly prevalent among patients of low socioeconomic backgrounds. Currently strategic goals of the TB programme in Namibia are mainly case identification and management with limited socioeconomic interventions among young adults in Namibia.

In conclusion, the study demonstrates a high prevalence LTFU among TB cases registered under the DOTS programme in Namibia, this is above the global target of 0%. The findings imply that main factors driving LTFU are related to socioeconomic welfare of young adults who seek temporary employment in regions that provide temporary working opportunities, including borders and capital towns. This age group is an important driver for HIV infection in Namibia. The study recommends the integration of socioeconomic interventions/incentives in DOTS programmes to support young adult TB cases in informal and/or temporary employments across all regions in Namibia. In addition, there is a need for integration of DOTS services in workplaces and institutions that provide temporary employment (*e.g.* construction sites) for mobile young male adults to enhance continuity of TB treatment and improve outcomes.
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